Phase III Study of ASP015K - A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to MTX
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Peficitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 07 Jun 2017 Biomarkers information updated
- 19 Apr 2017 Planned End Date changed from 1 Mar 2017 to 31 Jan 2018.
- 19 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 31 Jan 2018.